Joshua Wellington, MD
Interventional Pain Medicine · Carmel, INNPI 1588627251
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $275,663 of the $314,509 with a category attached, or 87.6%. Medtronic accounts for 99.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $80,978 and has fallen 86.8% since, to $10,682 in 2025. Among interventional pain medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 442 payments — averaging $711.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$311K
- Lilly USA, LLC$2K
- Boston Scientific$319
- Biotronik NRO, Inc.$194
- AbbVie$133
- Tersera Therapeutics LLC$132
- plus $241 from 9 others
Across 2 payments — averaging $6.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$12
What the payments were for
- Consulting fees$5,6402%
- Speaking & faculty fees$275,66388%
- Travel & lodging$24,3788%
- Food & beverage$8,8293%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 412 | $311,375 |
| Lilly USA, LLC | 2 | $2,116 |
| Boston Scientific | 3 | $319 |
| Biotronik NRO, Inc. | 2 | $194 |
| AbbVie | 6 | $133 |
| Tersera Therapeutics LLC | 5 | $132 |
| Collegium Pharmaceutical, Inc. | 3 | $51 |
| ANI Pharmaceuticals, Inc. | 2 | $38 |
| Painteq LLC | 1 | $34 |
| Tonix Medicines, Inc. | 1 | $29 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Vertex | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMED$87,092
- SYNCHROMEDII$63,780
- INTELLIS ADAPTIVESTIM$47,606
- INTELLIS$43,848
- VANTA ADAPTIVESTIM$27,006
- RESTORE$19,318
- ADAPTIVESTIM$7,500
- OSTEOCOOL RF ABLATION$6,875
- KYPHON Balloon Kyphoplasty$1,500
- RESTORESENSORSURESCAN$550
- Prospera$151
- WaveWriter Alpha Prime 16$135
How this compares
$314,509 in reported general payments places this provider in the 95th percentile of 68 interventional pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 21 | $16,438 |
| Fentanyl | 35 | $5,750 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 161 | $4,623 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 151 | $3,567 |
| Oxycodone Hcl | 141 | $2,797 |
| Hydromorphone Hcl | 91 | $2,527 |
| Morphine Sulfate ErMorphine Sulfate | 41 | $2,042 |
| Gabapentin | 93 | $1,880 |
| Vilazodone Hcl | 12 | $1,646 |
| Methadone Hcl | 52 | $1,446 |
| Pregabalin | 50 | $1,339 |
| Ondansetron OdtOndansetron | 36 | $1,277 |
| Diazepam | 47 | $1,186 |
| Lidocaine | 13 | $1,069 |
| Naloxone Hcl | 16 | $757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $51 | $16,43821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 interventional pain medicine providers in Indiana.
Other interventional pain medicine in Carmel
- Phillip KingmaCarmel$5K
- Dean MarianoCarmel$2K
- Joseph RutledgeLafayette$96K
- Orlando LandrumElkhart$34K
- Mahendra SanapatiEvansville$31K
- Nikhil ShettyMunster$29K
- David GordonIndianapolis$28K
- Vinayak BelamkarIndianapolis$28K
- Jocelyn BushIndianapolis$20K
- Scott KimGreenwood$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.